×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
Yahoo Finance
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin...
3 days ago
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
KLAS 8 News Now
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on...
2 days ago
What's Going On With Iovance Biotherapeutics Today? - Iovance Biotherapeutics (NASDAQ:IOVA)
Benzinga
On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline...
2 days ago
Institutional investors may overlook Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) recent US$112m market cap drop as long-term gains remain positive
Simply Wall Street
Key Insights Institutions' substantial holdings in Iovance Biotherapeutics implies that they have significant influence...
4 days ago
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
The Motley Fool
Iovance Biotherapeutics ... Is this rising healthcare stock a good buy right now? There's a lot of excitement around Iovance Biotherapeutics (IOVA...
1 month ago
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Reiterated by HC Wainwright
Defense World
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report)'s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a...
1 day ago
Lifileucel First Cellular Therapy Approved for Cancer
National Cancer Institute (.gov)
FDA has approved lifileucel (Amtagvi), the first cancer treatment that uses immune cells called tumor-infiltrating lymphocytes, or TILs.
2 months ago
Iovance Biotherapeutics Reports a Q1 Revenue Miss
The Motley Fool
Iovance Biotherapeutics (IOVA 0.10%), a pioneer in T-cell therapy, released its Q1 2024 earnings on Thursday, May 9, revealing outcomes that...
2 weeks ago
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
Yahoo Finance
Iovance Biotherapeutics IOVA announced updated clinical results from a cohort of the phase II IOV-COM-202 study evaluating the combination...
2 days ago
Is Iovance Biotherapeutics Stock a Buy Now?
The Motley Fool
Key Points. Iovance Biotherapeutics has a novel approach to developing cancer medicines. The small biotech recently earned approval for an...
1 month ago